Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 673

Similar articles for PubMed (Select 14630791)

1.

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Blood. 2004 Mar 15;103(6):2039-45. Epub 2003 Nov 20.

2.

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.

Blood. 1999 Sep 1;94(5):1550-4.

3.

Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.

Blood. 2002 Jan 1;99(1):10-4.

4.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
5.

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.

Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP, Girot R, Elion J.

Blood. 1998 Jun 15;91(12):4472-9.

7.

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Acta Haematol. 1995;94(3):128-34.

PMID:
7502628
8.

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Blood. 2010 Mar 25;115(12):2354-63. doi: 10.1182/blood-2009-05-221333. Epub 2009 Nov 10.

9.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

PMID:
8982148
10.

Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.

Rogers ZR.

Semin Hematol. 1997 Jul;34(3 Suppl 3):42-7.

PMID:
9317200
11.

Hydroxyurea in children: present and future.

Vichinsky EP.

Semin Hematol. 1997 Jul;34(3 Suppl 3):22-9. Review.

PMID:
9317198
12.

Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease.

Marcus SJ, Kinney TR, Schultz WH, O'Branski EE, Ware RE.

Am J Hematol. 1997 Jan;54(1):40-6.

PMID:
8980259
13.

A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.

Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE.

J Pediatr. 2001 Dec;139(6):790-6.

PMID:
11743503
14.

From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.

Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, Wang WC.

Medicine (Baltimore). 2014 Dec;93(28):e215. doi: 10.1097/MD.0000000000000215.

PMID:
25526439
15.

Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA.

Arch Pediatr Adolesc Med. 1994 Aug;148(8):796-804.

PMID:
7519102
16.

Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.

Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.

Blood Cells Mol Dis. 2009 Jan-Feb;42(1):25-31. doi: 10.1016/j.bcmd.2008.08.003. Epub 2008 Oct 26.

PMID:
18954999
17.

Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.

Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE.

Am J Hematol. 2013 Feb;88(2):116-9. doi: 10.1002/ajh.23365. Epub 2012 Dec 17.

PMID:
23255310
18.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
19.

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.

de Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakdjian J, Ducrocq R, Maier-Redelsperger M, Elion J, Labie D, Girot R.

J Pediatr Hematol Oncol. 1997 Jul-Aug;19(4):313-8.

PMID:
9256830
20.

Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.

Al-Jam'a AH, Al-Dabbous IA.

Saudi Med J. 2002 Mar;23(3):277-81.

PMID:
11938415
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk